Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-8.01 Insider Own5.20% Shs Outstand76.05M Perf Week-4.06%
Market Cap6.27B Forward P/E- EPS next Y-4.93 Insider Trans0.66% Shs Float70.59M Perf Month-18.71%
Income-570.30M PEG- EPS next Q-1.36 Inst Own97.30% Short Float19.25% Perf Quarter-36.47%
Sales344.60M P/S18.21 EPS this Y-533.90% Inst Trans1.93% Short Ratio7.99 Perf Half Y-32.51%
Book/sh14.86 P/B5.55 EPS next Y34.10% ROA-34.90% Target Price191.00 Perf Year-45.70%
Cash/sh14.50 P/C5.69 EPS next 5Y-0.20% ROE-55.40% 52W Range81.33 - 165.87 Perf YTD-24.39%
Dividend- P/FCF- EPS past 5Y-10.60% ROI-23.60% 52W High-50.26% Beta2.09
Dividend %- Quick Ratio7.80 Sales past 5Y84.10% Gross Margin85.50% 52W Low1.45% ATR4.49
Employees499 Current Ratio8.80 Sales Q/Q28.80% Oper. Margin- RSI (14)24.67 Volatility4.14% 4.47%
OptionableYes Debt/Eq0.00 EPS Q/Q-124.00% Profit Margin- Rel Volume1.13 Prev Close85.36
ShortableYes LT Debt/Eq0.39 EarningsAug 07 AMC Payout- Avg Volume1.70M Price82.51
Recom1.70 SMA20-7.09% SMA50-30.80% SMA200-33.16% Volume1,913,784 Change-3.34%
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-13-18Reiterated H.C. Wainwright Buy $75 → $92
Sep-20-19 03:20PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JE, ABMD and SRPT ACCESSWIRE
03:00PM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire
11:20AM  CLASS ACTION UPDATE for GTT, TWOU and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:44AM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Actions - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-19-19 02:35PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MNK, VAL and SRPT ACCESSWIRE
02:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
09:41AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of GTT, SRPT, TXT and VRAY GlobeNewswire
Sep-18-19 08:01PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, and Meredith Corporation and Encourages Investors to Contact the Firm GlobeNewswire
10:42AM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
10:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NFLX, CARB, TWOU and SRPT GlobeNewswire
05:36AM  After Boston speech, Ex-FDA chief defends record on vaping in interview American City Business Journals
12:04AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Sarepta Therapeutics, Inc. to Contact the Firm GlobeNewswire
Sep-17-19 09:01PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT GlobeNewswire
12:30PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of MNK, SRPT and MDP ACCESSWIRE
10:21AM  INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
10:02AM  CLASS ACTION UPDATE for MNK, CAH, GVA and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
12:05AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm ACCESSWIRE
Sep-16-19 10:00PM  Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and Encourages Sarepta Investors to Contact the Firm Business Wire
05:20PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of PS, TWOU and SRPT ACCESSWIRE
04:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
11:05AM  SHAREHOLDER ALERT: GVA VAL SRPT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:41AM  GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Sep-15-19 11:05AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CAH, IFF and SRPT ACCESSWIRE
Sep-14-19 07:20AM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Sep-13-19 11:46PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
03:30PM  CLASS ACTION UPDATE for LB, PS and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
03:00PM  SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: October 29, 2019 GlobeNewswire
03:00PM  IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:00AM  SHAREHOLDER ALERT: KPTI GTT SRPT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:20AM  INVESTOR ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: October 29, 2019 ACCESSWIRE
Sep-12-19 03:30PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PS, SRPT and TXT ACCESSWIRE
02:25PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT GlobeNewswire
02:15PM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
12:30PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CARB, VAL and SRPT ACCESSWIRE
10:55AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm GlobeNewswire
Sep-11-19 10:00PM  SHAREHOLDER ALERT: IFF SRPT TXT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
09:00PM  SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:30AM  CLASS ACTION UPDATE for CARB, EVH and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:50AM  INVESTOR ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Deadline: October 29, 2019 ACCESSWIRE
Sep-10-19 02:33PM  Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load? Simply Wall St. +5.11%
Sep-09-19 01:14PM  Here's Why Sarepta Therapeutics Dropped 39.4% in August Motley Fool
12:20PM  CLASS ACTION UPDATE for INS, NFLX and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:56AM  INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
10:48AM  SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Deadline: October 29, 2019 ACCESSWIRE
09:28AM  CLASS ACTION UPDATE for CTST, JE, VAL and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Sep-08-19 01:30PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
Sep-06-19 03:15PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of NFLX, NGHC and SRPT ACCESSWIRE
03:00PM  SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: October 29, 2019 GlobeNewswire
01:00PM  SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
12:10PM  CLASS ACTION UPDATE for NFLX, JE and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:30AM  IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:27AM  SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 29, 2019 ACCESSWIRE
09:31AM  Why Is Sarepta Therapeutics (SRPT) Down 33.1% Since Last Earnings Report? Zacks
09:30AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of MMM, GTT, PS and SRPT GlobeNewswire
Sep-05-19 11:37PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
08:30PM  SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE
06:22PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT GlobeNewswire
06:20PM  SHAREHOLDER ALERT: EGBN NTAP SRPT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
05:14PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
05:01PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT GlobeNewswire
04:30PM  Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program GlobeNewswire
02:30PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JE, EVH and SRPT ACCESSWIRE
12:20PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT) GlobeNewswire
11:52AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm PR Newswire
11:51AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of JE, CURLF and SRPT ACCESSWIRE
10:25AM  INVESTOR ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: October 29, 2019 ACCESSWIRE
Sep-04-19 05:35PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of RLGY, OMCL and SRPT ACCESSWIRE
02:20PM  CLASS ACTION UPDATE for JE, TWOU, EVH and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:16AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm GlobeNewswire
10:00AM  SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: October 29, 2019 PR Newswire
Sep-03-19 04:30PM  Sarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire
10:24AM  SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: October 29, 2019 ACCESSWIRE
Sep-02-19 02:48PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SRPT ACCESSWIRE
Aug-30-19 08:00PM  INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Sarepta Therapeutics, Inc. Business Wire
06:05PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
12:52PM  Pomerantz Law Firm Announces the Filing of a Class Action against Sarepta Therapeutics, Inc. and Certain Officers - SRPT GlobeNewswire
Aug-29-19 02:04PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT GlobeNewswire
Aug-27-19 05:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT ACCESSWIRE
Aug-24-19 09:16PM  Is Sarepta Therapeutics a Bad News Buy? Motley Fool
Aug-22-19 04:13PM  Why Analysts Are Upbeat On Sarepta Despite A Notable FDA Rejection Investor's Business Daily -6.33%
01:25PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sarepta Therapeutics, Inc. GlobeNewswire
11:55AM  The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron Zacks
11:29AM  Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock? Zacks
10:45AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sarepta Therapeutics, Inc. (SRPT) ACCESSWIRE
Aug-21-19 04:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT GlobeNewswire
12:40PM  FDA Rejection of Sarepta's Golodirsen Should Have Been Expected GuruFocus.com
11:21AM  Sarepta (SRPT) Stock Still Worth Over $200, Says Top Analyst TipRanks
11:00AM  Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More Zacks
09:52AM  Company News For Aug 21, 2019 Zacks
07:14AM  Sarepta shares are tanking after Duchenne drug setback MarketWatch
Aug-20-19 09:30PM  What's Next for Sarepta Therapeutics After Its Surprising FDA Rejection Motley Fool -15.16%
04:55PM  Stock Market Today: Beyond Meat Makes a Friend on Wall Street InvestorPlace
04:35PM  Why Madison Square Garden, Hain Celestial Group, and Sarepta Therapeutics Slumped Today Motley Fool
04:23PM  Why The FDA Left Sarepta To 'Twist In The Wind' Over Its Newest Drug Investor's Business Daily
02:35PM  Sarepta Therapeutics Stock Is Tumbling as the FDA Questions Its Newest Muscular Dystrophy Drug Barrons.com
12:59PM  Analysts Unfazed By FDA Snub Of Sarepta's DMD Drug, Pin Hopes On Gene Therapy Benzinga
12:20PM  Sarepta's FDA rejection could have ripple effect in other Duchenne biotechs American City Business Journals
12:02PM  Sarepta Plunges After FDA Spurns Its Second Duchenne Muscular Dystrophy Drug Benzinga
12:02PM  Parents Push One Rare-Disease Drug Through FDA, Not Its Successor Bloomberg
10:45AM  Sarepta Stock Falls as FDA Denies Approval to Golodirsen Zacks
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company's pipeline comprise SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA. It has collaboration agreements with Nationwide Children's Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; Galgt2, a gene therapy program for the treatment of DMD; and Neutrophin 3, a gene therapy program to treat Charcot-Marie-Tooth neuropathies. The company also has a license agreement with Lysogene to develop LYS-SAF302, a gene therapy for mucopolysaccharidosis IIIA; a license and option agreement with Lacerta to develop treatments for CNS-targeted and lysosomal storage diseases; and research collaboration and option agreement with Genethon to develop micro-dystrophin gene therapy products. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a collaboration agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline; a strategic collaboration with Paragon Bioservices; and a strategic collaboration with CENTOGENE for the identification of patients with DMD in the Middle East and North Africa region. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Barry RichardDirectorSep 13Buy87.493,309289,5043,187,065Sep 16 08:00 AM
Barry RichardDirectorSep 12Buy87.491,691147,9503,183,756Sep 16 08:00 AM
BONNEY MICHAEL WDirectorSep 09Buy86.742,000173,4807,051Sep 09 02:18 PM
BEHRENS M KATHLEENDirectorSep 06Buy87.982,500219,950125,667Sep 06 02:13 PM
BEHRENS M KATHLEENDirectorSep 05Option Exercise7.805,00039,000123,167Sep 06 02:13 PM
Mahatme SandeshEVP, CFO & CBOAug 21Option Exercise23.85100,0002,385,000130,179Aug 22 07:20 PM
Barry RichardDirectorAug 20Buy99.325,000496,5933,182,065Aug 20 05:43 PM
Mahatme SandeshEVP, CFO & CBOAug 15Option Exercise24.739,754241,23230,179Aug 15 04:33 PM
Barry RichardDirectorAug 14Buy122.503,700453,2503,177,065Aug 14 04:38 PM
INGRAM DOUGLAS SPresident & CEOAug 12Buy123.0716,2522,000,160432,197Aug 12 05:48 PM
Barry RichardDirectorAug 12Buy122.501,300159,2503,173,365Aug 13 04:31 PM
Wigzell Hans Lennart RudolfDirectorMay 23Option Exercise7.8010,00078,00021,717May 24 08:03 PM
Wigzell Hans Lennart RudolfDirectorMay 23Sale120.0010,0001,200,00011,717May 24 08:03 PM
Mahatme SandeshEVP, CFO & CBOMar 19Option Exercise21.4615,486332,30819,354Mar 20 08:00 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Option Exercise23.8565,0001,550,25073,649Feb 08 08:02 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Sale145.0065,0009,425,0008,649Feb 08 08:02 PM
Howton David TSVP, General CounselFeb 01Option Exercise21.6521,500465,39149,571Feb 01 08:25 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Option Exercise22.547,500169,03530,266Feb 01 08:27 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Sale140.0015,0002,100,00015,266Feb 01 08:27 PM
Howton David TSVP, General CounselFeb 01Sale140.0030,0004,200,00019,571Feb 01 08:25 PM
Mahatme SandeshEVP, CFO & CBOJan 31Option Exercise23.8521,198505,57229,847Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 31Sale130.7221,1982,771,0038,649Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Option Exercise18.2743,802800,07752,451Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Sale130.0043,8025,694,2608,649Feb 01 08:24 PM
Wigzell Hans Lennart RudolfDirectorNov 01Option Exercise8.946,66759,60316,751Nov 02 06:01 PM
Wigzell Hans Lennart RudolfDirectorNov 01Sale140.506,667936,71410,084Nov 02 06:01 PM
BEHRENS M KATHLEENDirectorOct 31Option Exercise3.9610,00039,600126,534Nov 02 06:00 PM
BEHRENS M KATHLEENDirectorOct 31Sale131.7110,0001,317,100116,534Nov 02 06:00 PM
INGRAM DOUGLAS SPresident & CEOOct 30Buy120.3916,6952,009,872415,945Oct 30 07:05 PM
Mahatme SandeshEVP, CFO & CBOOct 24Option Exercise14.8889,4001,330,389128,185Oct 26 06:43 PM
Mahatme SandeshEVP, CFO & CBOOct 24Sale127.74107,52413,735,11620,661Oct 26 06:43 PM